Skip to main content
Back to Trials
NCT07792941PHASE1RecruitingAccepts Healthy Volunteers

A Study to Learn About the Single Dose Pharmacokinetics of Study Medicine Called Tilrekimig in Healthy Adults When Co-Mixed With rHuPH20

Pfizer

Start Date

8/27/2026

Completion Date

2/11/2027

Summary

This study aims to learn how the body handles tilrekimig when given with another medicine called recombinant human hyaluronidase PH20 (rHuPH20). rHuPH20 is approved to help some medicines be taken up by the body when they are given together as an injection (shot) under the skin.

Eligibility Criteria

Age Range: 18 years to 65 years

Inclusion Criteria: * BMI of 16-32 kg/m2; and a total body weight \>50 kg (110 lb). * Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures. Participants should be able to understand and sign informed consent Exclusion Criteria: * Evidence or history of clinically significant any medical condition * History of HIV infection, hepatitis B, or hepatitis C; positive testing for HIV, HBsAg, HBcAb or HCVAb. * Evidence of active, latent, or inadequately treated infection with Mycobacterium TB * History of allergic or anaphylactic reaction with any biologic agents.

Interventions

DRUG

tilrekimig and rHuPH20

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Healthy

Locations

New Haven Pfizer Clinical Research Unit (NH PCRU)

New Haven, Connecticut 06511

United States